10-K: Marpai Inc. Reports Annual Results for 2024, Cites Going Concern Uncertainty

Marpai Inc.'s 2024 annual report reveals a net loss, revenue decline, and an auditor's note raising substantial doubt about the company's ability to continue as a going concern.

Summary

• Marpai Inc.'s annual report for the fiscal year ended December 31, 2024, indicates a net loss of $22.1 million, compared to a net loss of $28.8 million in the previous year.
• Revenue decreased by 24% to $28.2 million, primarily due to customer turnover.
• The company's independent auditor, UHY LLP, included an explanatory paragraph in their report expressing substantial doubt about Marpai's ability to continue as a going concern.
• As of December 31, 2024, Marpai had an accumulated deficit of $98.8 million and negative working capital of $7.1 million.
• The company had $6.1 million in short-term debt and $20.7 million in long-term debt, with unrestricted cash of $764 thousand.
• Marpai is seeking additional funding through equity or debt securities and may consider selling non-strategic assets.
• The company incurred a $7.6 million impairment charge related to goodwill and intangible assets.
• Adjusted EBITDA for 2024 was a loss of $9.1 million, compared to a loss of $20.2 million in 2023.
• The company's shares are now trading on the OTCQX Market under the symbol MRAI after being suspended from trading on Nasdaq.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with declining revenue, net losses, and a going concern warning, offset slightly by cost-cutting measures and efforts to secure additional funding. The overall sentiment is negative.

Positives

• The net loss decreased from $28.8 million in 2023 to $22.1 million in 2024.
• Adjusted EBITDA improved, with a loss of $9.1 million in 2024 compared to a loss of $20.2 million in 2023.
• The company is actively pursuing additional funding and considering asset sales to improve its financial position.
• General and administrative expenses decreased by $6.4 million due to actions taken to align the two TPA companies.

Negatives

• The auditor's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• Revenue decreased by 24% to $28.2 million due to customer turnover.
• The company had an accumulated deficit of $98.8 million and negative working capital of $7.1 million as of December 31, 2024.
• Marpai incurred a $7.6 million impairment charge related to goodwill and intangible assets.
• The company's stock was suspended from trading on Nasdaq and is now trading on the OTCQX Market.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring operating losses and negative cash flows.
• Failure to obtain additional capital could materially and adversely impact the company's ability to operate and invest in its product portfolio.
• High customer attrition rates could negatively impact future revenue growth and operating results.
• The company operates in a highly competitive industry, and the size of its target market may not remain as large as anticipated.
• The company relies on healthcare benefits brokers and consultants, who may direct clients to other TPAs if not satisfied.
• Government regulation of healthcare creates risks and challenges with respect to compliance efforts and business strategies.
• Breaches in security measures or unauthorized access to client data could lead to significant liabilities and reputational damage.

Future Outlook

The company projects that it will need additional capital to fund its current operations and capital investment requirements until it reaches a revenue level that permits cash self-sufficiency, with the sources of this capital anticipated to be from the sale of equity and/or debt securities.

Management Comments

• Management has determined that our liquidity condition raises substantial doubt about our ability to continue as a going concern through twelve months from the date these consolidated financial statements are available to be issued.

Industry Context

The report notes that U.S. private health insurance spending reached $1.5 trillion in 2023, highlighting the significant market opportunities for cost management and service providers in the healthcare sector.

Comparison to Industry Standards

• The report mentions that Marpai competes with nearly 1,000 health insurance entities, indicating a highly competitive market.
• The company provides administrative services to self-insured employers, who can elect to abandon self-insurance and buy medical insurance from large players such as Aetna, Cigna, or United Healthcare.
• The TPA industry has thousands of companies across the United States with the vast majority being less sophisticated small regional players.

Legal Proceedings

• By letter dated September 3, 2020, the CMS notified Marpai Administrators of a complaint alleging that Marpai Administrators uses a clearinghouse (Zelis) that charges a percentage-based fee for Electronic Funds Transfer (EFT) transactions, which potentially violates HIPAA, 45 CFR 162.923(a).

Related Party Transactions

• On December 14, 2023, the company entered into a securities purchase agreement with HillCour, pursuant to which the company agreed to issue and sell 150,000 shares of our common stock in a private placement.
• On January 16, 2024, the company entered into a securities purchase agreement with certain insiders consisting of HillCour, our Chairman, Yaron Eitan, and our director, Robert Pons, pursuant to which the company agreed to issue and sell 1,322,100 shares of our common stock in a private placement.
• On March 7, 2024, the company entered into a securities purchase agreement with HillCour, pursuant to which the company agreed to issue and sell 910,000 shares of our common stock in a private placement.
• On August 28, 2024, the Company entered into a securities purchase agreement with two investors, including HillCour, pursuant to which the Company agreed to issue and sell an aggregate of 2,702,702 shares of our common stock (of which HillCour purchased 1,351,351 shares of common stock) in a private placement.
• On December 5, 2024, the company entered into a securities purchase agreement with four investors, including Yaron Eitan, our Chairman, Steve Johnson, our Chief Financial Officer and John Powers, our President and Chief Operating Officer, pursuant to which the Company agreed to issue and sell an aggregate of 621,194 shares of our common stock (of which Mr. Eitan purchased 110,619 shares of common stock, Mr. Johnson purchased 5,000 shares of common stock and Mr. Powers purchased 10,000 shares of common stock) in a private placement.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures or asset sales.
• Clients may be concerned about the company's long-term viability and service continuity.
• Creditors face increased risk due to the company's high debt levels and uncertain financial outlook.

Next Steps

• The company will seek to raise additional funds through the issuance of equity or debt securities.
• The company will continue to evaluate additional funding alternatives.
• The company may seek to sell assets which it regards as non-strategic.

Key Dates

Keywords

financial results, annual report, going concern, revenue, net loss, EBITDA, Marpai, OTCQX, debt, capital, TPA, healthcare